Potential novel mechanisms for AD therapies in patients with peripheral hyperinsulinemia include reducing the load of insulin on IDE in the brain, either by increasing the affinity of IDE for Aβ or by decreasing brain insulin concentrations. The gene discussed is INS; the disease is Hyperinsulinemia.